Navigating 2L Treatment Options in CLL

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

EP: 1.Patient with Newly Diagnosed CLL with High-Risk Features

EP: 2.Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

EP: 3.Navigating Continuous BTKi Therapy for CLL in the 1L Setting

EP: 4.Implications of Real-World Data in the 1L Treatment of High-Risk CLL

EP: 5.Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

EP: 6.Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

EP: 7.Perspectives on Shared Decision-Making in the Treatment of CLL

EP: 8.Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

EP: 9.Expert Insights for Long-Term Treatment Planning in CLL

EP: 10.Patient with R/R CLL Treated with 2L Venetoclax Therapy

Now Viewing

EP: 11.Navigating 2L Treatment Options in CLL

EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

EP: 13.Management Strategies for BTKi-Related CVAEs in CLL

EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis

EP: 15.Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following questions:

What is your general treatment approach in patients with R/R CLL?
- How does prior 1L therapy influence your treatment decision?
- How does your approach to 2L treatment differ from 3L+?
- In what clinical scenarios may you consider venetoclax for patients with R/R CLL?